Verseon Corporation (AIM:VERS)

5:15 PM - 5:30 PM, Monday, June 3, 2019 ・ Theater 1
Verseon Corporation (AIM:VERS) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational platform with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation (currently in phase 1), diabetic macular edema, hereditary angioedema, and oncology.
Ticker:
VERS
Exchange:
AIM
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
Not Provided.
Main Therapeutic Focus:
Lead Product in Development:
VE-4840
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
Senior Director of Discovery Biology
Verseon